Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Genetic Screens02:46

Genetic Screens

Genetic screens are tools used to identify genes and mutations responsible for phenotypes of interest. Genetic screens help identify individuals or a group of people at risk of developing  genetic diseases and help them with early intervention, targeted therapy, and reproductive options.
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which result in visible changes...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Biological Clocks: Ready for Prime Time?

Journal of insurance medicine (New York, N.Y.)·2026
Same author

AI in Healthcare: How Relevant to Medical Risk Selection?

Journal of insurance medicine (New York, N.Y.)·2026
Same author

When Is a Test Genetic? The Case of Multi-Cancer Early Detection Tests.

Journal of insurance medicine (New York, N.Y.)·2026
Same author

Long Covid in Year 5: Some Progress, Still Many Questions.

Journal of insurance medicine (New York, N.Y.)·2025
Same author

Critical Illness Insurance: In Search of Its Identity.

Journal of insurance medicine (New York, N.Y.)·2025
Same author

Autoimmune Diseases following COVID-19 Infection: How Solid is the Evidence?

Journal of insurance medicine (New York, N.Y.)·2024

Related Experiment Video

Updated: Jun 18, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

When Is a Test "Genetic?" The Case of Multi-Cancer Early Detection Tests.

Timothy Meagher

    Journal of Insurance Medicine (New York, N.Y.)
    |June 17, 2026
    PubMed
    Summary

    Multi-cancer early detection (MCED) tests are not typically considered genetic tests. Therefore, insurers may not be restricted from using MCED results in risk assessments under current genetic testing legislation.

    Keywords:
    Epigenetic testFragmentomicsGenetic TestGermline testingHereditary genetic disorderMetabolomicsMethylation patternsMulti-cancer early detection testProteomicsSomatic testing

    More Related Videos

    Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
    05:53

    Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

    Published on: June 21, 2018

    Related Experiment Videos

    Last Updated: Jun 18, 2026

    Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
    06:21

    Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

    Published on: May 10, 2024

    Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
    05:53

    Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry

    Published on: June 21, 2018

    Area of Science:

    • Medical diagnostics
    • Health policy
    • Genetics

    Background:

    • Multi-cancer early detection (MCED) tests are gaining popularity for proactive health screening.
    • The classification of MCED tests as "genetic" impacts their regulatory and insurance implications.
    • Existing legislation often restricts insurer access to genetic testing data for risk assessment.

    Purpose of the Study:

    • To determine if Multi-cancer early detection (MCED) tests qualify as "genetic tests" under current legal definitions.
    • To analyze the legislative intent behind restricting insurer access to genetic testing information.
    • To examine whether MCED test results fall under existing legislative protections in three English-speaking jurisdictions.

    Main Methods:

    • Review of established definitions for "genetic tests."
    • Analysis of legislative frameworks in three English-speaking jurisdictions concerning genetic information.
    • Comparative legal analysis to ascertain the inclusion of MCED tests within these frameworks.

    Main Results:

    • MCED tests, which analyze circulating tumor DNA, do not consistently meet the narrow definitions of "genetic tests" as typically defined in legislation.
    • The primary motivation for legislative restrictions is to prevent genetic discrimination based on inherited predispositions.
    • Current legislation in the reviewed jurisdictions does not explicitly include MCED test results.

    Conclusions:

    • MCED tests are unlikely to be classified as "genetic tests" under most current legal definitions.
    • Insurers may not be legally prohibited from accessing and utilizing MCED test results for risk assessment purposes.
    • Further legislative clarification or new regulations may be needed to address the unique nature of MCED tests.